MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

3α-Aminocholestane

CAS No. : 2206-20-4

MCE 国际站：3α-Aminocholestane

产品活性：3α-Aminocholestane 是含有选择性 SH2 结构域的肌醇-5'-磷酸酶 1 (SHIP1) 的抑制剂，其 IC₅₀ 值约为 2.5 μM。

研究领域：Metabolic Enzyme/Protease

作用靶点：Phosphatase

In Vitro: OPM2 cell viability is effectively reduced by 3α-Aminocholestane (3AC) treatment. RPMI8226 and U266 cells show significantly less sensitivity to 3α-Aminocholestane treatment when compare with OPM2 cells, although viability is decreased significantly at concentrations of ≥12.5 μM. Treatment with 3α-Aminocholestane for 36 h severely reduces the percentage of cells in the S phase, which is accompanied by an increase of cells in the G2/M phase. In contrast, in the less proliferative RPMI8226 and U266 cells, cell cycle progression is blocked in the G0/G1 phase upon 3α-Aminocholestane treatment, in conjunction with a reduced percentage of cells undergoing the S phase.

In Vivo: It is found that 3α-Aminocholestane (3AC) results in reduced multiple myeloma (MM) growth in vivo, as determined by quantitation of free human Igλ light chain in the plasma after OPM2 challenge. In addition, reduced numbers of circulating OPM2 cells, as determined by human HLA-ABC staining, is observed in peripheral blood from 3α-Aminocholestane-treated mice compare with vehicle controls. Most importantly, 3α-Aminocholestane treatment results in significantly enhanced survival of mice after tumor challenge. In 3α-Aminocholestane-treated mice that resist treatment, it is found that MM tumors exhibit an upregulation of SHIP2, reminiscent of in vitro treatment of OPM2 cells and suggesting that SHIP1 inhibition may select for tumor cells with increased SHIP2 expression.

相关产品：Bioactive Compound Library Plus  |  Metabolism/Protease Compound Library  |  Anti-Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Phosphatase Inhibitor Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Highly Selective Inhibitors Library  |  BN82002  |  Rubrofusarin 6-O-β-D-glucopyranoside  |  RMC-3943  |  GNF362  |  MY10  |  D-erythro-Sphingosine  |  AS1949490  |  NTPDase-IN-1  |  SHP099 hydrochloride  |  Ertiprotafib  |  Trimyristin--d₁₅  |  SMAP-2  |  cyt-PTPε Inhibitor-1  |  Raphin1 acetate  |  Calyculin A  |  Endothall  |  Razuprotafib  |  Icerguastat  |  Methyl pseudolarate B  |  5-FAM-Alkyne  |  Calcium glycerophosphate  |  Trichomide A  |  PTP1B-IN-21  |  PFKFB3-IN-2  |  CCT007093  |  BVT948  |  L-690330 hydrate  |  SPI-112  |  EWP 815  |  PTPN2/1-IN-1

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

货号: HY-19776

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。